Table 4. Hazard Ratios for Gene-Chemotherapy Interactions among Specific Chemotherapy-Treated and Untreated Patients.
| Drug | Gene | Variant | Genotypes1 | HR (95%CI)2 | P interaction | |
|---|---|---|---|---|---|---|
| Treated | Untreated | |||||
| 5-FU | ||||||
| TYMS | rs2847153 | AA/(AG+GG) | 2.56(1.33-4.95) | 0.83(0.63-1.10) | 0.0012 | |
| ERCC1 | rs11615 | CC/(CT+TT) | 0.51(0.29-0.92) | 1.36(1.07-1.72) | 0.0040 | |
| UGT1A7 | rs1604144 | CC/(CT+TT) | 0.33(0.13-0.85) | 1.43(1.09-1.89) | 0.0055 | |
| XRCC1 | rs939461 | AA/(AC+CC) | 3.95(1.45-10.75) | 0.79(0.57-1.10) | 0.0068 | |
| CDKN2A | rs3731217 | GG/(GT+TT) | 0.29(0.12-0.69) | 0.99(0.69-1.41) | 0.015 | |
| CDKN1A | rs876581 | AA/(AG+GG) | 2.95(1.07-8.13) | 0.81(0.54-1.23) | 0.018 | |
| CHRNA3 | rs6495309 | CC/(CT+TT) | 0.36(0.16-0.84) | 0.97(0.74-1.28) | 0.024 | |
| ERCC5 | rs4150351 | AA/(AC+CC) | 0.43(0.21-0.88) | 0.96(0.68-1.35) | 0.033 | |
| MMP3 | rs645419 | AA/(AG+GG) | 2.46(1.31-4.60) | 1.22(0.98-1.52) | 0.036 | |
| UGT1A1 | rs4148328 | CC/(CT+TT) | 0.57(0.30-1.11) | 1.19(0.92-1.52) | 0.038 | |
| Gemcitabine | ||||||
| GPT | rs1063739 | AA/(AC+CC) | 1.34(0.96-1.87) | 0.71(0.51-0.98) | 0.0076 | |
| GSTP1 | rs6591256 | AA/(AG+GG) | 1.17(0.86-1.59) | 0.64(0.45-0.90) | 0.011 | |
| CDA | rs12404655 | AA/(AG+GG) | 1.22(0.82-1.82) | .61(0.40-0.93) | 0.018 | |
| IQGAP2 | rs153317 | CC/(CT+TT) | 1.05(0.79-1.39) | 1.80(1.26-2.58) | 0.019 | |
| GABRA4 | rs1512130 | AA/(AG+GG) | 0.89(0.63-1.25) | 1.49(1.06-2.08) | 0.036 | |
| XRCC2 | rs3218527 | AA/(AC+CC) | 14.8(1.68-130.2) | 0.51(0.10-2.49) | 0.038 | |
| Erlotinib | ||||||
| DCTD | rs17074237 | AA/(AG+GG) | 0.28(0.08-0.97) | 1.96(1.18-3.25) | 0.0013 | |
| MET | rs2237717 | CC/(CT+TT) | 3.23(1.67-6.24) | 1.05(0.84-1.31) | 0.0017 | |
| SLC29A1 | rs324148 | CC/(CT+TT) | 1.38(0.86-2.19) | 0.66(0.51-0.86) | 0.010 | |
| CDKN1A | rs876581 | AA/(AG+GG) | 3.23(0.92-11.35) | 0.86(0.57-1.30) | 0.029 | |
| MSH2 | rs10495944 | AA/(AG+GG) | 2.12(0.78-5.72) | 0.76(0.53-1.10) | 0.049 | |
| Capecitabine | ||||||
| MMP3 | rs645419 | AA/(AG+GG) | 0.44(0.16-1.19) | 1.38(1.12-1.71) | 0.023 | |
| SERPINA3 | rs17091162 | AA/(AC+CC) | 4.35(1.64-11.54) | 1.46(1.09-1.94) | 0.032 | |
| Cisplatin/Oxaliplatin | ||||||
| GGH | rs4617146 | CC/(CT+TT) | 3.70(1.21-11.34) | 0.81(0.62-1.06) | 0.014 | |
| MMP3 | rs645419 | AA/(AG+GG) | 0.56(0.24-1.28) | 1.37(1.11-1.70) | 0.036 | |
1
Reference genotype/risk genotypes
2
Adjusted for age, sex, race, stage, and other treatments